Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Формат:	Өгүүллэг
Хэл сонгох:	English
Хэвлэсэн:	Wiley 2019-10-01
Цуврал:	Cancer Medicine
Нөхцлүүд:	anaplastic lymphoma kinase inhibitor crizotinib crizotinib continuation beyond progressive disease non‐small cell lung cancer treatment duration
Онлайн хандалт:	https://doi.org/10.1002/cam4.2420

Ижил төстэй зүйлс

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
-н: Carolina Valeria Mahuad, зэрэг
Хэвлэсэн: (2016-06-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
-н: Emei GAO, зэрэг
Хэвлэсэн: (2016-03-01)

The Use of Crizotinib in Sclerosing Epithelioid Fibrosarcoma with ALK Mutation: A Case Report
-н: Ahmed Badran, зэрэг
Хэвлэсэн: (2023-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
-н: Tao JIANG, зэрэг
Хэвлэсэн: (2015-02-01)

ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
-н: Moushumi Suryavanshi, зэрэг
Хэвлэсэн: (2017-01-01)

Efficacy of different sequential patterns after crizotinib progression in advanced anaplastic lymphoma kinase‐positive non–small cell lung cancer
-н: Xiya Ma, зэрэг
Хэвлэсэн: (2022-06-01)

Crizotinib in treatment of lung cancer
-н: Arpita Singh, зэрэг
Хэвлэсэн: (2017-01-01)

Unusual Late Relapse of ALK-Positive Anaplastic Large Cell Lymphoma Successfully Cleared Using the ALK-Inhibitor Crizotinib: Case Report
-н: Dennis Christoph Harrer, зэрэг
Хэвлэсэн: (2020-10-01)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
-н: Yuka Kuriyama, зэрэг
Хэвлэсэн: (2013-08-01)

Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
-н: Caiyu Lin, зэрэг
Хэвлэсэн: (2021-12-01)

Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center
-н: Chang Liu, зэрэг
Хэвлэсэн: (2019-10-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
-н: Chan-Young Ock, зэрэг
Хэвлэсэн: (2019-09-01)

The Dual Role of Autophagy in Crizotinib-Treated ALK<sup>+</sup> ALCL: From the Lymphoma Cells Drug Resistance to Their Demise
-н: Estelle Espinos, зэрэг
Хэвлэсэн: (2021-09-01)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
-н: Muhammad Wasi Alam, зэрэг
Хэвлэсэн: (2019-07-01)

Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China
-н: Zihua Zou, зэрэг
Хэвлэсэн: (2022-01-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
-н: Henan BAI, зэрэг
Хэвлэсэн: (2021-08-01)

Crizotinib for recurring non‐small‐cell lung cancer with EML4‐ALK fusion genes previously treated with alectinib: A phase II trial
-н: Daijiro Harada, зэрэг
Хэвлэсэн: (2021-03-01)

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
-н: Scott N. Gettinger, MD, зэрэг
Хэвлэсэн: (2022-09-01)

Real‐world outcome of crizotinib for anaplastic lymphoma kinase‐positive lung cancer: Multicenter retrospective analysis in South Korea
-н: Da Som Jeon, зэрэг
Хэвлэсэн: (2024-02-01)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
-н: Tomonobu Koizumi, зэрэг
Хэвлэсэн: (2016-04-01)

Crizotinib-Associated Renal Cysts: A Case Series
-н: Garima Suman, зэрэг
Хэвлэсэн: (2019-07-01)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
-н: Woo Kyung Ryu, зэрэг
Хэвлэсэн: (2022-10-01)

A Case of Orbital Metastasis as Disease Progression of Anaplastic Lymphoma Kinase-Positive Lung Cancer Treated with Crizotinib
-н: Yoshihiko Sakata, зэрэг
Хэвлэсэн: (2015-01-01)

Efficacy and safety of crizotinib in patients with anaplastic lymphoma kinase-positive advanced-stage non-small-cell lung cancer
-н: Mohieldin A, зэрэг
Хэвлэсэн: (2018-11-01)

Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib
-н: Di Marino P, зэрэг
Хэвлэсэн: (2020-03-01)

Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung
-н: Anurag Mehta, зэрэг
Хэвлэсэн: (2017-01-01)

Clinical characteristics and risk factors of drug‐induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis
-н: Ken Koshikawa, зэрэг
Хэвлэсэн: (2020-06-01)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
-н: Jun Osugi, зэрэг
Хэвлэсэн: (2016-01-01)

Clinical Efficacy of Crizotinib in Advanced ALK Positive  Non-small Cell Lung Cancer
-н: Jing ZHAO, зэрэг
Хэвлэсэн: (2015-10-01)

Modern treatment of ALK-positive non-small cell lung cancer
-н: D. A. Kharagezov, зэрэг
Хэвлэсэн: (2022-06-01)

Identification of a novel ALK variant intrinsically resistant to crizotinib
-н: Ullas Batra, зэрэг
Хэвлэсэн: (2020-12-01)

Efficacy and Safety of Crizotinib in Advanced or Recurrent  ALK-positive Non-small Cell Lung Cancer
-н: Xiaoyan LI, зэрэг
Хэвлэсэн: (2019-08-01)

Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature
-н: Peng Zhang, зэрэг
Хэвлэсэн: (2024-04-01)

Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL
-н: Wanying Liu, зэрэг
Хэвлэсэн: (2024-02-01)

Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence
-н: Yurong Wang, зэрэг
Хэвлэсэн: (2022-12-01)

Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐naïve ALK‐positive non‐small‐cell lung cancer
-н: Giacomina Megaro, зэрэг
Хэвлэсэн: (2022-03-01)

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study
-н: Caicun Zhou, MD, PhD, зэрэг
Хэвлэсэн: (2024-09-01)

Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib
-н: Yuhang Zhou, зэрэг
Хэвлэсэн: (2023-11-01)

Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
-н: Julia Barbara Bargieł, зэрэг
Хэвлэсэн: (2021-09-01)

A Case of Lung Adenocarcinoma Harboring a Rare LOC285000-ALK-NCK2 Gene Fusion Identified by Next-Generation Sequencing With Long-Term Response to Crizotinib
-н: Min Zhang, MBBS, зэрэг
Хэвлэсэн: (2021-02-01)